Nephrol Dial Transplant (2002) 17: 1005-1013
© 2002 European Renal Association-European Dialysis and Transplant Association
Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease
1 Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow-Klinikum, Berlin, 2 Bayer Research Centre, Uerdingen, 3 Department of Nephrology, Gilead II Hospital, Bielefeld and 4 Bayer Vital GmbH, Leverkusen, Germany
Background. Chronic kidney disease is characterized by increased synthesis and inhibited destruction of collagenous and non-collagenous matrix proteins. Elevation of collagen fragments has been demonstrated in the serum and urine of patients with renal disease, but the dynamics of renal matrix deposition remain difficult to determine.
Methods. To obtain a further insight into renal matrix metabolism we have assessed whether serum and urine concentrations of the non-collagenous protein, tenascin, and of the tissue inhibitor of metalloproteinases 1 (TIMP-1) are altered in association with renal disease. Serum and urine concentrations of both proteins were determined using a newly developed magnetic particle enzyme immunoassay and were compared with levels of N-terminal procollagen III-peptide (PIIINP) and related to the degree of renal failure and proteinuria.
Results. Circulating levels of tenascin and TIMP-1 were moderately, but significantly, higher in patients with chronic renal disease (n=54; mean creatinine clearance, 62 ml/min) than in healthy controls (n=176). Urine concentrations per mg creatinine of tenascin and TIMP-1 were significantly lower than serum levels, but were on average six- and 18-fold higher, respectively, in patients with renal disease than in controls. Urinary concentrations increased with progressive reduction in renal function, but were unrelated to proteinuria. TIMP-1 concentrations in urine correlated with tenascin, which is compatible with the impact of TIMP-1 on the accumulation of matrix proteins. The concentrations of proteins measured did not differ depending on the aetiology of renal disease.
Conclusion. Urinary concentrations of tenascin and TIMP-1 are elevated in association with renal disease and may reflect specific aspects of renal fibrosis.
Keywords: procollagen III-peptide; renal fibrosis; serum; tenascin; tissue inhibitor of metalloproteinases-1; urine
Correspondence and offprint requests to: K.-U. Eckardt, MD, Department of Nephrology and Medical Intensive Care, Charité, Humboldt Universität, Campus Virchow Klinikum, Augustenburger Platz 1, D-13353 Berlin, Germany. Email: kai\|[hyphen]\|uwe.eckardt{at}charite.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Sieber, D. Hoffmann, M. Adler, V. S. Vaidya, M. Clement, J. V. Bonventre, N. Zidek, E. Rached, A. Amberg, J. J. Callanan, et al. Comparative Analysis of Novel Noninvasive Renal Biomarkers and Metabonomic Changes in a Rat Model of Gentamicin Nephrotoxicity Toxicol. Sci., June 1, 2009; 109(2): 336 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Catania, G. Chen, and A. R. Parrish Role of matrix metalloproteinases in renal pathophysiologies Am J Physiol Renal Physiol, March 1, 2007; 292(3): F905 - F911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. F. Sanders, H. van Goor, R. Hanemaaijer, C. G. M. Kallenberg, and C. A. Stegeman Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1412 - 1419. [Abstract] [Full Text] [PDF]
|
|